About
NOXXON’s oncology-focused pipeline acts on the tumor microenvironment (TME) and the cancer immunity cycle by breaking the tumor protection barrier and blocking tumor repair. By neutralizing chemokines in the tumor microenvironment, NOXXON’s approach works in combination with other forms of treatment to...
NOXXON’s oncology-focused pipeline acts on the tumor microenvironment (TME) and the cancer immunity cycle by breaking the tumor protection barrier and blocking tumor repair. By neutralizing chemokines in the tumor microenvironment, NOXXON’s approach works in combination with other forms of treatment to weaken tumor defenses against the immune system and enable greater therapeutic impact. Building on extensive clinical experience and safety data, the lead program NOXA12 has delivered top-line data from a Keytruda® combination trial in metastatic colorectal and pancreatic cancer patients and further studies are being planned in these indications. In September 2019 the company initiated an additional trial with NOX-A12 in brain cancer in combination with radiotherapy. The combination of NOX-A12 and radiotherapy has been granted orphan drug status in the US and EU for the treatment of certain brain cancers. The company’s second clinical-stage asset NOX-E36 is a Phase 2 TME asset targeting the innate immune system. NOXXON plans to test NOX-E36 in patients with solid tumors both as a monotherapy and in combination. Further information can be found at: www.noxxon.com Keytruda® is a registered trademark of Merck Sharp & Dohme Corp
  • 29
    Oct
    20
    News Release
    NOXXON Publishes Interim 2020 Results | NOX-A12 combination trials advancing well and balance sheet strengthened
  • 28
    Oct
    20
    News Release
    NOXXON announces completion of 6-month therapy for low-dose cohort in Phase 1/2 brain cancer study of NOX-A12 plus radiotherapy
  • 20
    Oct
    20
    News Release
    NOXXON announces three additional clinical centers to recruit patients for NOX-A12 brain cancer trial
  • 14
    Oct
    20
    News Release
    NOXXON announces successful completion of patient recruitment for second dose cohort in phase 1/2 brain cancer study of NOX-A12 plus radiotherapy
  • 14
    Oct
    20
    News Release
    NOXXON secures expanded capacity and improved conversion conditions for convertible bonds from Atlas
  • 17
    Sep
    20
    News Release
    NOXXON presents final clinical data from phase 1/2 NOX-A12 / Keytruda combination trial in colorectal and pancreatic cancer at the ESMO virtual congress 2020
  • 17
    Sep
    20
    Company Presentation
    Innovative Clinical Programs Targeting the Tumor Microenvironment to Improve Therapeutic Outcomes in Underserved Solid Tumors
  • 12
    Aug
    20
    News Release
    NOXXON to present final clinical data from the NOX-A12 / Keytruda combination trial in colorectal and pancreatic cancer at the ESMO virtual congress 2020
  • 24
    Jul
    20
    News Release
    NOXXON announces first brain cancer patient from second dose cohort reaches 4 weeks of treatment with NOX-A12 combined with radiotherapy
  • 13
    Jul
    20
    News Release
    Half-yearly report on the liquidity contract with Invest Securities
  • 3
    Jul
    20
    Company Presentation
    Innovative Clinical Programs Targeting the Tumor Microenvironment to Improve Therapeutic Outcomes in Underserved Solid Tumors
  • 2
    Jul
    20
    News Release
    NOXXON announces appointment of Oscar Izeboud to the supervisory board and provides results of the annual general shareholders meeting
  • 1
    Jul
    20
    Equity Research
    NOXXON Pharma (EPA:ALNOX) Research Initiation
  • 30
    Jun
    20
    News Release
    NOXXON enrolls first patient in the second dose cohort of trial combining NOX-A12 with radiotherapy in newly diagnosed brain cancer
  • 16
    Jun
    20
    News Release
    NOXXON announces capital increase of Euro 1.3 million by private placement to further develop its business
  • 12
    Jun
    20
    News Release
    NOXXON announces issuance of tranches of Convertible Bonds under financing agreement with Atlas
  • 29
    May
    20
    News Release
    NOXXON announces convocation of the hybrid annual general meeting of shareholders
  • 8
    May
    20
    News Release
    NOXXON announces capital increase of EUR 5.5 million by private placement to further develop its business
  • 6
    May
    20
    News Release
    NOXXON announces issuance of a tranche of Convertible Bonds under financing agreement with Atlas
  • 3
    May
    20
    Company Presentation
    Innovative Clinical Programs Targeting the Tumor Microenvironment to Improve Therapeutic Outcomes in Underserved Solid Tumors - May 2020
  • 27
    Apr
    20
    News Release
    NOXXON presents latest clinical data from the Phase 1/2 NOX-A12 / Keytruda combination trial in colorectal and pancreatic cancer at the AACR Virtual Annual Meeting 2020
  • 24
    Apr
    20
    News Release
    NOXXON announces that Data Safety Monitoring Board validates NOX-A12 dose escalation in Phase 1/2 brain cancer study
  • 23
    Apr
    20
    News Release
    NOXXON secures financing of up to 14.2 million Euro through convertible bonds from Atlas
  • 22
    Apr
    20
    News Release
    NOXXON Pharma N.V. reports 2019 financial results
  • 20
    Apr
    20
    News Release
    NOXXON announces complete conversion of Acuitas warrants
  • 14
    Apr
    20
    News Release
    NOXXON to present latest clinical data from the NOX-A12 / KEYTRUDA combination trial in colorectal and pancreatic cancer at the AACR Virtual Annual Meeting 2020
  • 2
    Apr
    20
    News Release
    NOXXON announces completion of patient recruitment for the first dose cohort in the phase 1/2 brain cancer study of NOX-A12 plus radiotherapy
  • 31
    Mar
    20
    News Release
    NOXXON provides update on clinical trial recruitment and corporate operations during COVID-19 pandemic
  • 4
    Mar
    20
    Company Presentation
    Presentation
  • 20
    Jan
    20
    News Release
    NOXXON announces another capital increase of 0.5 million Euro through a private placement of shares
  • 16
    Jan
    20
    News Release
    Half-yearly report on the liquidity contract with Invest Securities
  • 14
    Jan
    20
    News Release
    NOXXON announces a capital increase of 0.5 million Euro through a private placement of shares
  • 20
    Dec
    19
    News Release
    NOXXON announces first brain cancer patient reaches 10 weeks of treatment with NOX-A12 plus radiotherapy
  • 30
    Oct
    19
    Corporate Update
    Half-Year Financial Report as of 30 June 2019
  • 24
    Oct
    19
    News Release
    NOXXON publishes interim 2019 results
  • 16
    Oct
    19
    News Release
    NOXXON enrolls first patient in the phase 1/2 clinical trial combining NOX-A12 with radiotherapy in newly diagnosed brain cancer
  • 30
    Sep
    19
    Company Presentation
    ESMO Congress 2019 Poster Presentation
  • 29
    Sep
    19
    News Release
    NOXXON presents latest clinical data from Phase 1/2 NOX-A12 / Keytruda combination trial at the ESMO congress
  • 23
    Sep
    19
    Company Presentation
    Presentation
  • 18
    Sep
    19
    News Release
    NOXXON to present latest clinical data from NOX-A12 / Keytruda combination trial at the ESMO congress
  • 12
    Sep
    19
    News Release
    NOXXON initiates patient recruitment for phase 1/2 clinical trial combining NOX-A12 & radiotherapy for the treatment of brain cancer patients
  • 15
    Aug
    19
    News Release
    NOXXON announces completion of EUR 1 million capital increase
  • 6
    Aug
    19
    News Release
    NOXXON announces a capital increase of Euro 1 million through a private placement of shares without warrants
  • 22
    Jul
    19
    News Release
    Half-yearly report on the liquidity contract with Invest Securities
  • 19
    Jul
    19
    News Release
    NOXXON raises amount of Euro 521 K in its rights issue
  • 27
    Jun
    19
    News Release
    Results of NOXXON annual general shareholders meeting
  • 26
    Jun
    19
    News Release
    NOXXON announces launch of capital increase right issue for an amount of up to Euro 3.9 M
  • 24
    Jun
    19
    News Release
    NOXXON announces leading international pharma to evaluate NOX-A12 in new indication
  • 24
    May
    19
    News Release
    NOXXON announces convocation of the annual general meeting of shareholders
  • 13
    May
    19
    Company Presentation
    Corporate Presentation
  • 3
    May
    19
    News Release
    NOXXON announces change within supervisory board
  • 12
    Apr
    19
    News Release
    NOXXON Pharma N.V. reports 2018 financial results
  • 12
    Apr
    19
    Corporate Update
    2018 Annual Report
  • 1
    Apr
    19
    News Release
    NOXXON presents updated results from Phase 1/2 NOX-A12 / Keytruda combination trial at AACR 2019
  • 1
    Apr
    19
    News Release
    NOXXON presents updated results from Phase 1/2 NOX-A12 / Keytruda combination trial at AACR 2019
  • 27
    Feb
    19
    News Release
    NOXXON files application for phase 1/2 clinical trial combining NOX-A12 & radiotherapy for the treatment of brain cancer
  • 18
    Feb
    19
    News Release
    NOXXON publishes a shareholder letter
  • 1
    Feb
    19
    News Release
    New data published supporting monotherapy activity of CCL2 inhibitor NOX-E36 in an additional solid tumor type: liver cancer
  • 14
    Jan
    19
    News Release
    Half-yearly report on the liquidity contract with Invest Securities
  • 4
    Jan
    19
    News Release
    Results of NOXXON's extra-ordinary general meeting of shareholders
  • 30
    Oct
    18
    Corporate Update
    Half-Year Financial Report as of 30 June 2018
  • 30
    Apr
    18
    Corporate Update
    2017 Annual Report